- Case report
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Amiodarone-induced reversible and irreversible hepatotoxicity: two case reports
© The Author(s). 2018
Received: 26 January 2018
Accepted: 21 February 2018
Published: 14 April 2018
Amiodarone is a highly effective treatment for supraventricular and ventricular tachyarrhythmia; however, it could be associated with several serious adverse effects, including liver injury.
We report the clinical and histological features of two contrasting Japanese patients with amiodarone-induced reversible and irreversible hepatotoxicity. One patient with amiodarone-induced irreversible hepatotoxicity showed liver cirrhosis during treatment with amiodarone and died of hepatic failure; the other patient, who had reversible hepatotoxicity, showed a reversible course of liver function and imaging after discontinuation of amiodarone.
We emphasize the importance of close monitoring of liver enzymes and evaluation of liver computed tomographic imaging as well as liver biopsy during treatment with amiodarone, and discontinuation should be considered when amiodarone-induced hepatotoxicity is suspected.
Amiodarone is a highly effective treatment for supraventricular and ventricular tachyarrhythmia; however, it could be associated with several serious adverse effects, including pulmonary toxicity , thyroid dysfunction , and liver injury . Serious adverse effects sometimes result in a poor prognosis because of the very long plasma half-life of amiodarone. Amiodarone-induced hepatotoxicity can progress to cirrhosis, resulting in decompensated hepatic failure, although this rarely happens . In this report, we present the clinical features of two patients with amiodarone-induced reversible and irreversible hepatotoxicity, highlighting the importance of close monitoring of liver enzymes and evaluation of liver computed tomographic (CT) images as well as liver biopsy during treatment with amiodarone.
At admission, the patient’s blood pressure was 95/66 mmHg, his heart rate was 69 beats/minute, and his body temperature was 35.6 °C. His consciousness was clear, and his respiratory sounds were normal. Marked distention of the abdomen was observed, and the liver and spleen were palpable from the abdominal wall. No abnormal neurological finding was observed.
A chest x-ray revealed mild cardiomegaly (cardiothoracic ratio 50%) without marked congestion and pleural effusion. Echocardiography showed mild left ventricular systolic dysfunction (ejection fraction 45%) and mild mitral and tricuspid regurgitation without a finding of pulmonary hypertension. Blood tests showed thrombocytopenia (81 × 103/μl), elevations of liver and ductal enzymes (aspartate aminotransferase 135 IU/L, alanine aminotransferase 91 IU/L, γ-glutamyl transpeptidase [γ-GTP] 202 IU/L, total bilirubin 2.4 md/dl), and hypoalbuminemia (serum albumin 3.1 g/dl). The patient’s brain natriuretic peptide level was mildly elevated (136 pg/ml), which showed no change during follow-up. Other serologic study results were negative for chronic viral hepatitis and other liver diseases. An abdominal plain CT scan showed massive ascites and splenomegaly, in addition to diffuse high attenuation of the liver parenchyma (Fig. 1b). At that time, amiodarone was discontinued because amiodarone-induced hepatotoxicity was suspected. However, the patient died of hepatic insufficiency during hospitalization. An autopsy revealed yellow liver specimens with a rough surface that suggested cirrhotic changes. Hematoxylin and eosin staining showed regenerative nodules and well-developed bridging fibrosis. Marked neutrophilic infiltrates, a remarkable amount of Mallory bodies, and hepatocellular ballooning were observed (Fig. 1c). Moreover, electron microscopic examination detected numerous whorled or lamellar bodies in the lysosomes (Fig. 1d). These findings helped diagnose amiodarone-induced hepatotoxicity associated with irreversible liver cirrhosis.
Patient 2 was a 74-year-old Japanese man who underwent hemodialysis for chronic renal failure and was admitted to our hospital because of asymptomatic liver enzyme elevation. He had been working for the government, had never smoked, and had no history of alcohol abuse. He had no apparent family history of cardiovascular or liver diseases. At admission, his blood pressure was 126/52 mmHg, his heart rate was 46 beats/minute, and his body temperature was 36.4 °C. Physical and neurological examinations yielded no abnormal findings. Blood tests showed anemia (hemoglobin 11.5 g/dl), elevations of liver and ductal enzymes (aspartate aminotransferase 189 IU/L, alanine aminotransferase 150 IU/L, γ-GTP 1009 IU/L), elevation of C-reactive protein (1.04 mg/dl), and renal dysfunction (creatinine 3.34 mg/dl at 1 day after his regular hemodialysis). A chest x-ray revealed no abnormal findings. Echocardiography showed mild left ventricular systolic dysfunction (ejection fraction 48%) without any apparent structural diseases.
In this report, we present the clinical features of two patients with amiodarone-induced reversible and irreversible hepatotoxicity, highlighting the importance of close monitoring of liver enzymes and evaluation of liver CT imaging as well as liver biopsy during treatment with amiodarone. Approximately 25% of patients using amiodarone develop a transient asymptomatic increase in serum aminotransferase levels that resolves spontaneously or after dose reduction . Amiodarone-induced symptomatic hepatitis, cirrhosis, and fatal hepatic failure are extremely rare (0–3%) [4, 5]. However, when the diagnosis is established, the mortality risk may be as high as 60% at 5 months . Histological features of amiodarone-induced hepatotoxicity are similar to alcoholic hepatitis and characterized by Mallory bodies, leukocyte infiltration, steatosis, and ballooning of hepatocytes . Amiodarone and its metabolites accumulate in lysosomes of hepatocytes and lead to inhibition of phospholipase A1 and A2, which inhibits removal of lysosomal lipids and leads to phospholipidosis . As with our patients, this mechanism leads to steatohepatitis and finally to irreversible liver cirrhosis. The presence of lamellar lysosomal inclusion bodies visualized by electron microscopy is a typical pathological finding of amiodarone-induced hepatotoxicity . In patient 1, amiodarone was continued under the conditions of elevated liver enzymes in addition to the use of corticosteroids that could cause liver injury or accelerate his underlying liver injury, and it led to irreversible fatal hepatic failure. However, in patient 2, amiodarone was discontinued immediately after the detection of liver enzyme elevation and led to improvement of liver function. According to these two clinical courses, amiodarone should be discontinued immediately if amiodarone-induced liver injury is suspected.
Amiodarone is a lipophilic agent and tends to accumulate in lipid-laden organelles such as the liver. It is reported that a concentration of amiodarone and its metabolite, N-desethylamiodarone, in the liver may be as high as 500-fold of the serum level .
Previous reports showed that the plasma amiodarone level may be poorly correlated with its toxicity . However, high liver density seen on CT scans, which is secondary to increased iodine content of amiodarone and reflects the tissue level of amiodarone, may be useful to detect the toxicity . In this regard, it is important to evaluate elevations of liver enzymes, liver CT imaging (high attenuation of the liver parenchyma), and histology, and discontinuation should be considered when amiodarone-induced hepatotoxicity is suspected. Alternative strategies, such as catheter ablation and/or an implantable cardioverter defibrillator implant could be considered for such patients.
Amiodarone-induced hepatotoxicity showed a reversible or irreversible course, depending on when or if the drug was discontinued. Close monitoring of liver enzymes and evaluation of liver CT imaging and liver biopsy results should be considered, and amiodarone should be discontinued when amiodarone-induced hepatotoxicity is suspected.
Availability of data and materials
All data generated or analyzed during this study are included in this published article.
All authors contributed to the patients’ care, preparation of the images, and writing/reviewing of the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The publication of this case report was approved by the clinical research ethics committees of Kanazawa University Hospital.
Consent for publication
Written informed consent was obtained from the patients or their relatives for publication of this case report and any accompanying images. A copy of the written consents is available for review by the Editor-in-Chief of this journal.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation. 1990;82:51–9.View ArticlePubMedGoogle Scholar
- Shiga T, Wakaumi M, Matsuda N, et al. Amiodarone-induced thyroid dysfunction and ventricular tachyarrhythmias during long-term therapy in Japan. Jpn Circ J. 2001;65:958–60.View ArticlePubMedGoogle Scholar
- Mason JW. Amiodarone. N Engl J Med. 1987;316:455–66.View ArticlePubMedGoogle Scholar
- Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology. 1989;9:679–85.View ArticlePubMedGoogle Scholar
- Richer M, Robert S. Fatal hepatotoxicity following oral administration of amiodarone. Ann Pharmacother. 1995;29:582–6.View ArticlePubMedGoogle Scholar
- Hussain N, Bhattacharyya A, Prueksaritanond S. Amiodarone-induced cirrhosis of liver: what predicts mortality? ISRN Cardiol. 2013;2013:617943.PubMedPubMed CentralGoogle Scholar
- Lewis JH, Mullick F, Ishak KG, et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol. 1990;21:59–67.View ArticlePubMedGoogle Scholar
- Martin WJ 2nd, Kachel DL, Vilen T, Natarajan V. Mechanism of phospholipidosis in amiodarone pulmonary toxicity. J Pharmacol Exp Ther. 1989;251:272–8.PubMedGoogle Scholar
- Brien JF, Jimmo S, Brennan FJ, Ford SE, Armstrong PW. Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. Can J Physiol Pharmacol. 1987;65:360–4.View ArticlePubMedGoogle Scholar
- Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B, Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Practical guidelines for clinicians who treat patients with amiodarone. Arch Intern Med. 2000;160:1741–8.View ArticlePubMedGoogle Scholar
- Kim BB, Kim DM, Choi DH, et al. Amiodarone toxicity showing high liver density on CT scan with normal liver function and plasma amiodarone levels in a long-term amiodarone user. Int J Cardiol. 2014;172:494–5.View ArticlePubMedGoogle Scholar